287 related articles for article (PubMed ID: 36943819)
41. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation.
Lopez LM; Grey TW; Stuebe AM; Chen M; Truitt ST; Gallo MF
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD003988. PubMed ID: 25793657
[TBL] [Abstract][Full Text] [Related]
42. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
Vinogradova Y; Coupland C; Hippisley-Cox J
BMJ; 2015 May; 350():h2135. PubMed ID: 26013557
[TBL] [Abstract][Full Text] [Related]
43. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
[TBL] [Abstract][Full Text] [Related]
44. Prescription contraceptives: countering the risks.
Ruggiero RJ
Am Pharm; 1985 Sep; NS25(9):32-7. PubMed ID: 4050670
[TBL] [Abstract][Full Text] [Related]
45. Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
Cohen MA; Edelman A; Paynter R; Henderson JT
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014908. PubMed ID: 36622724
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer and hormone-replacement therapy in the Million Women Study.
Beral V;
Lancet; 2003 Aug; 362(9382):419-27. PubMed ID: 12927427
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer before age 45 and oral contraceptive use: new findings.
Miller DR; Rosenberg L; Kaufman DW; Stolley P; Warshauer ME; Shapiro S
Am J Epidemiol; 1989 Feb; 129(2):269-80. PubMed ID: 2912040
[TBL] [Abstract][Full Text] [Related]
48. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women.
Sweeney C; Giuliano AR; Baumgartner KB; Byers T; Herrick JS; Edwards SL; Slattery ML
Int J Cancer; 2007 Dec; 121(11):2517-23. PubMed ID: 17657739
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for triple-negative breast cancer in women under the age of 45 years.
Dolle JM; Daling JR; White E; Brinton LA; Doody DR; Porter PL; Malone KE
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1157-66. PubMed ID: 19336554
[TBL] [Abstract][Full Text] [Related]
50. Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.
Chie WC; Li CY; Huang CS; Chang KJ; Yen ML; Lin RS
Int J Cancer; 1998 Jul; 77(2):219-23. PubMed ID: 9650556
[TBL] [Abstract][Full Text] [Related]
51. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
van Hylckama Vlieg A; Helmerhorst FM; Vandenbroucke JP; Doggen CJ; Rosendaal FR
BMJ; 2009 Aug; 339():b2921. PubMed ID: 19679614
[TBL] [Abstract][Full Text] [Related]
52. Contraception for women with diabetes: an update.
Skouby SO; Mølsted-Pedersen L; Petersen KR
Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
[TBL] [Abstract][Full Text] [Related]
53. Risk factors for fatal venous thromboembolism in young women: a case-control study.
Thorogood M; Mann J; Murphy M; Vessey M
Int J Epidemiol; 1992 Feb; 21(1):48-52. PubMed ID: 1544757
[TBL] [Abstract][Full Text] [Related]
54. Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals.
Hariton E; Shirazi TN; Douglas NC; Hershlag A; Briggs SF
Am J Obstet Gynecol; 2021 Nov; 225(5):515.e1-515.e10. PubMed ID: 34126087
[TBL] [Abstract][Full Text] [Related]
55. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.
Lopez LM; Grimes DA; Schulz KF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006133. PubMed ID: 22513937
[TBL] [Abstract][Full Text] [Related]
56. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
Parkin L; Sharples K; Hernandez RK; Jick SS
BMJ; 2011 Apr; 342():d2139. PubMed ID: 21511804
[TBL] [Abstract][Full Text] [Related]
57. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.
Wu O; Robertson L; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Langhorne P; Brenkel I; Regan L; Greer I
Health Technol Assess; 2006 Apr; 10(11):1-110. PubMed ID: 16595080
[TBL] [Abstract][Full Text] [Related]
58. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
Krashin J; Tang JH; Mody S; Lopez LM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
[TBL] [Abstract][Full Text] [Related]
59. Oral contraceptives and breast cancer: latest findings in a large cohort study.
Vessey MP; McPherson K; Villard-Mackintosh L; Yeates D
Br J Cancer; 1989 Apr; 59(4):613-7. PubMed ID: 2713247
[TBL] [Abstract][Full Text] [Related]
60. Hormonal contraception and pelvic girdle pain during pregnancy: a population study of 91,721 pregnancies in the Norwegian Mother and Child Cohort.
Bjelland EK; Kristiansson P; Nordeng H; Vangen S; Eberhard-Gran M
Hum Reprod; 2013 Nov; 28(11):3134-40. PubMed ID: 23887071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
